HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ESBA105

a single-chain Fv antibody that inhibits inflammation and prevents cartilage damage triggered by TNFalpha

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        ESBA105: 2
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        ESBA105: 2
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        ESBA105: 2

Experts

1.	Alcantara, Wolfan: 1 article (07/2013)
2.	Bochmann, Frank: 1 article (07/2013)
3.	Escher, Dominik: 1 article (07/2013)
4.	Job, Oliver: 1 article (07/2013)
5.	Lichtlen, Peter: 1 article (07/2013)
6.	Loukopoulos, Vlasios: 1 article (07/2013)
7.	Schmid, Martin K: 1 article (07/2013)
8.	Schmidt, Annette: 1 article (07/2013)
9.	Thiel, Michael A: 1 article (07/2013)
10.	Wild, Andreas: 1 article (07/2013)

Related Diseases

1.	Necrosis 02/01/2010 - "(1) To show that a single-chain Fv antibody (scFv) against tumour necrosis factor alpha (TNFalpha) (ESBA105) has efficacy comparable to a full length anti-TNFalpha IgG (infliximab); (2) to evaluate whether ESBA105 has all the properties required for the local treatment of arthritis; and (3) to investigate its discriminative tissue penetration properties. "
2.	Inflammation (Inflammations) 02/01/2010 - "ESBA105 potently inhibits inflammation and prevents cartilage damage triggered by TNFalpha. " 02/01/2010 - "In vivo, ESBA105 inhibited rhTNFalpha-induced synovial inflammation in rats with efficacy again comparable to infliximab. "
3.	Cataract (Cataracts) 07/01/2013 - "ESBA105 (n = 57) or placebo (n = 22) was preoperatively applied as eye drops to 1 eye in patients scheduled for cataract surgery (n = 73) or combined cataract surgery and vitrectomy (n = 6). "
4.	Arthritis (Polyarthritis) 02/01/2010 - "In contrast to a full length IgG, ESBA105 also penetrates into cartilage and can be expected to reverse the TNFalpha-induced catabolic state of articular cartilage in arthritides." 02/01/2010 - "(1) To show that a single-chain Fv antibody (scFv) against tumour necrosis factor alpha (TNFalpha) (ESBA105) has efficacy comparable to a full length anti-TNFalpha IgG (infliximab); (2) to evaluate whether ESBA105 has all the properties required for the local treatment of arthritis; and (3) to investigate its discriminative tissue penetration properties. "

Related Drugs and Biologics

1.	Single-Chain Antibodies
2.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
3.	Ophthalmic Solutions (Eye Drops)
4.	Immunoglobulin G (IgG)
5.	Infliximab (Remicade)

Related Therapies and Procedures

1.	Vitrectomy